Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Skye Bioscience Inc SKYE

Healthcare Biotechnology
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation... see more

Recent & Breaking News (NDAQ:SKYE)

Nemus Bioscience, Inc. Signs Agreement with Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredient for Glaucoma

GlobeNewswire August 1, 2018

Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors

GlobeNewswire July 20, 2018

Nemus Bioscience to Participate at the 8th Annual LD Micro Invitational

GlobeNewswire May 30, 2018

Nemus Bioscience Adds to Senior Leadership Team

GlobeNewswire May 7, 2018

Prominent Salk Institute Neuroscientist Joins Nemus Bioscience as Scientific Consultant

GlobeNewswire March 21, 2018

NEMUS Bioscience to Participate in Sachs BioCapital USA Forum at the New York Academy of Sciences

GlobeNewswire March 7, 2018

Emerald Health, Strategic Majority Investor in Nemus Bioscience, Completes Final Closing of Private Placement Investment Ahead of Schedule

GlobeNewswire February 16, 2018

NEMUS Bioscience to Participate in BIO CEO Investor Conference to Provide Ophthalmology-Focused Pipeline Review

GlobeNewswire February 7, 2018

Nemus Secures Emerald Health as Strategic Majority Investor to help Advance Clinical Development of Novel Cannabinoid-based Therapeutics

GlobeNewswire January 19, 2018

Nemus Bioscience Announces Closing of Convertible Bridge Loan and Anticipated Equity Financing

GlobeNewswire December 29, 2017

Nemus Bioscience Files Arbitration Petition Against Schneider Finance, LLC and SB Securities, Ltd. for Failure to Close $20 Million Financing and Failure to Honor Guarantee

Marketwired November 9, 2017

NEMUS Bioscience Announces Presentation of CBD-analogue Therapeutic Data Related to Neuropathic Pain (NB2111) and Ocular Diseases (NB2222) at Upcoming Scientific Meetings

Marketwired November 6, 2017

Nemus Bioscience Announces $2,000,000 Series F Preferred Stock Financing

Marketwired November 1, 2017

NEMUS Bioscience Provides Further Update on Previously Announced $20 Million Schneider Financing

Marketwired October 13, 2017

NEMUS Bioscience Announces Presentation of CBD-analogue (NB2222) Ocular Data at the AAPS 2017 Annual Meeting

Marketwired August 7, 2017

Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference

Marketwired August 2, 2017

NEMUS Bioscience Announces NB2222 Pain and Anti-Addiction Data Accepted for Presentation at Upcoming Society of Neuroscience Meeting

Marketwired July 17, 2017

Nemus Bioscience Announces NB1111 Data Presentation at the 27th Annual Symposium of the International Cannabinoid Research Society (ICRS)

Marketwired June 22, 2017

Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Issued Patent Coverage in Canada and Hong Kong

Marketwired May 17, 2017

Cannabinoid-Based Therapeutics Company Nemus Just Received $20 Million To Develop Its Drugs

Benzinga.com  May 13, 2017